MPX Bioceutical Buys Canadian LP Canveda

cannabis market report

A US-based and focused cannabis operator has completed a deal to buy a licensed producer (LP) in Canada, marking its official entry into the Canadian space.

MPX Bioceutical (CSE:MPX, OTC:MPXEF) announced on Monday (June 11) it had reached an agreement for the acquisition of all issued and outstanding shares of Canveda, a company that obtained its cultivation license last year.

Canveda’s LP asset is a 12,000 square foot facility in Peterborough, Ontario currently projected to produce 1,000-1,200 kilograms of cannabis flower per year.

Looking for Cannabis Stocks?
Read our report to find market data, important news and stocks to watch!

Give me my free report!

Details of the transaction

According to its statement, MPX will pay roughly C$18.1 million in a combination of C$3.1 million in cash, C$15 million worth of common shares issued at C$0.70 and 6 million common share purchase warrants.

“With the acquisition of Canveda, MPX has established a foothold in Canada to develop a vertically integrated business from seed to sale,” Michael Arnkvarn, executive vice president and chief marketing officer said in the statement.

During a conference call to update analysts and investors on the acquisition and general developments of the company, MPX also revealed it had reached US$5 million in revenue in March for its presence in Arizona and Nevada.

In the past, MPX has been clear with its intentions in the Canadian market by owning an Ontario facility in the application stage to become an LP. That process then stagnated which caused the company to direct its attention into the US market.

Now with the Canveda acquisition, MPX CEO Scott Boyes said it should help accelerate the process to obtain cultivation, sale and dealer licenses for the Owen Sound, Ontario facility.

On the same call, Boyes was asked how Continue Reading

Comments are closed.